David M. Schuster

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

Ian Law, Nathalie L. Albert, Javier Arbizu et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 516 citations · Full text

Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

David M. Schuster, John R. Votaw, Peter T. Nieh et al. · PubMed · 2007 · 275 citations

Hyperspectral imaging and quantitative analysis for prostate cancer detection

Hamed Akbari, Luma V. Halig, David M. Schuster et al. · Journal of Biomedical Optics · 2012 · 263 citations · Full text

Urology, Image Analysis, Hyperspectral Data +15

Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer

Arnold C. Paulino, Mary Koshy, Rebecca M. Howell et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 260 citations

Adaptive Radiotherapy, Radiation Therapy, Medical Imaging +10